(Q34088403)

30 July 2017

1 reference

title

Decitabine in the treatment of myelodysplastic syndromes. (English)

1 reference

30 July 2017

2

Hagop Kantarjian

1 reference

30 July 2017

5

Farhad Ravandi

1 reference

30 July 2017

Guillermo Garcia-Manero

series ordinal

3

object named as

Guillermo Garcia-Manero

1 reference

30 July 2017

4

Jean-Pierre Issa

1 reference

30 July 2017

Fabio P S Santos

1

1 reference

30 July 2017

publication date

1 January 2010

1 reference

Expert Review of Anticancer Therapy

30 July 2017

published in

1 reference

30 July 2017

volume

10

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

9-22

1 reference

The myelodysplastic syndromes: diagnosis and treatment

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Gene silencing in cancer in association with promoter hypermethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

The fundamental role of epigenetics in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Cellular differentiation, cytidine analogs and DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Demethylating agents in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Cytosine arabinoside influx and nucleoside transport sites in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Kinetics of phosphorylation of 5-aza-2′-deoxycytidine by deoxycytidine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Pharmacology of 5-Aza-2'-deoxycytidine (decitabine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

5-AZA-2′-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Inhibition of DNA methylation and reactivation of silenced genes by zebularine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

An ATM- and Rad3-related (ATR) signaling pathway and a phosphorylation-acetylation cascade are involved in activation of p53/p21Waf1/Cip1 in response to 5-aza-2'-deoxycytidine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Histone deacetylase inhibitors: molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

HDAC inhibitors: clinical update and mechanism-based potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.164

21 January 2018

Identifiers

DOI

10.1586/ERA.09.164

1 reference

30 July 2017

1 reference